Company Description
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States.
The company’s clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.
Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases.
Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine.
The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017.
Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.
| Country | United States |
| Founded | 1995 |
| IPO Date | Apr 6, 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 405 |
| CEO | Alexander Macrae |
Contact Details
Address: 501 Canal Blvd Richmond, California 94804 United States | |
| Phone | 510 970 6000 |
| Website | sangamo.com |
Stock Details
| Ticker Symbol | SGMO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001001233 |
| CUSIP Number | 800677106 |
| ISIN Number | US8006771062 |
| Employer ID | 68-0359556 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D. | Chief Executive Officer, President and Director |
| Prathyusha Duraibabu CPA, M.B.A. | Senior Vice President, Chief Financial Officer and Principal Accounting Officer |
| Dr. Nathalie Dubois-Stringfellow Ph.D. | Senior Vice President and Chief Development Officer |
| Gregory Davis Ph.D. | Head of Research and Technology |
| Aron Feingold | Head of Corporate Communications and Investor Relations Officer |
| Scott B. Willoughby | Senior Vice President, General Counsel and Corporate Secretary |
| Phillip Ramsey | Head of Technical Operations |
| Stephanie J. Seiler CLP | Head of Business Development and Alliance Management |
| David Ojala | Scientist II - Discovery and Translational Research |
| Louise Wilkie | Vice President of Investor Relations and Corporate Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 10, 2024 | 8-K | Current Report |
| Nov 19, 2024 | EFFECT | Notice of Effectiveness |
| Nov 18, 2024 | UPLOAD | Filing |
| Nov 12, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 12, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 4, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 4, 2024 | 8-K | Current Report |